Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.

Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX.

J Natl Compr Canc Netw. 2019 Feb;17(2):141-147. doi: 10.6004/jnccn.2018.7094.

PMID:
30787127
2.

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

Patel DA, Xi J, Luo J, Hassan B, Thomas S, Ma CX, Campian JL.

Breast Cancer Res Treat. 2019 Apr;174(2):443-452. doi: 10.1007/s10549-018-05106-7. Epub 2019 Jan 2.

PMID:
30604000
3.

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.

Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N.

Nat Genet. 2019 Feb;51(2):207-216. doi: 10.1038/s41588-018-0287-5. Epub 2018 Dec 10.

PMID:
30531871
4.

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.

Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW.

FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.

PMID:
30161001
5.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

6.

Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis.

Liu N, Johnson KJ, Ma CX.

Clin Breast Cancer. 2018 Oct;18(5):e997-e1002. doi: 10.1016/j.clbc.2018.06.013. Epub 2018 Jun 27.

PMID:
30007834
7.

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS.

Breast Cancer Res Treat. 2018 Aug;170(3):547-557. doi: 10.1007/s10549-018-4770-6. Epub 2018 Apr 19.

PMID:
29675680
8.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

PMID:
29472518
9.

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.

Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA.

Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13.

PMID:
29442264
10.

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, Ma CX, Lapi SE.

Oncotarget. 2017 Nov 1;8(61):104303-104314. doi: 10.18632/oncotarget.22228. eCollection 2017 Nov 28.

11.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

12.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

13.

CDK4/6 inhibition triggers anti-tumour immunity.

Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ.

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

14.

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ.

Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.

15.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

16.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
17.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

18.

The role of neratinib in HER2-driven breast cancer.

Cherian MA, Ma CX.

Future Oncol. 2017 Jun 30. doi: 10.2217/fon-2017-0186. [Epub ahead of print]

PMID:
28665682
19.

Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.

Hsu CD, Wang X, Habif DV Jr, Ma CX, Johnson KJ.

Cancer. 2017 Aug 15;123(16):3125-3131. doi: 10.1002/cncr.30722. Epub 2017 Apr 25.

20.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

21.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.

Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.

22.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

23.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

24.

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.

Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX.

Breast Cancer Res Treat. 2017 Feb;161(3):491-499. doi: 10.1007/s10549-016-4062-y. Epub 2016 Dec 3.

25.

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX.

Oncotarget. 2016 Aug 30;7(35):56864-56875. doi: 10.18632/oncotarget.10870.

26.

The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment.

Wolf TJ, Doherty M, Kallogjeri D, Coalson RS, Nicklaus J, Ma CX, Schlaggar BL, Piccirillo J.

Oncology. 2016;91(3):143-52. doi: 10.1159/000447744. Epub 2016 Jul 23.

27.

Chemotherapy principles of managing stage IV breast cancer in the United States.

Hernandez-Aya LF, Ma CX.

Chin Clin Oncol. 2016 Jun;5(3):42. doi: 10.21037/cco.2016.04.01. Epub 2016 Apr 14. Review.

28.

Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.

Ma CX, Bose R, Ellis MJ.

Adv Exp Med Biol. 2016;882:125-54. doi: 10.1007/978-3-319-22909-6_5. Review.

PMID:
26987533
29.

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ.

Clin Cancer Res. 2016 Jun 1;22(11):2650-8. doi: 10.1158/1078-0432.CCR-15-2160. Epub 2016 Jan 18.

30.

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Ma CX, Luo J, Naughton M, Ademuyiwa F, Suresh R, Griffith M, Griffith OL, Skidmore ZL, Spies NC, Ramu A, Trani L, Pluard T, Nagaraj G, Thomas S, Guo Z, Hoog J, Han J, Mardis E, Lockhart C, Ellis MJ.

Clin Cancer Res. 2016 Apr 1;22(7):1583-91. doi: 10.1158/1078-0432.CCR-15-1745. Epub 2015 Nov 12.

31.

The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.

Suman VJ, Ellis MJ, Ma CX.

Chin Clin Oncol. 2015 Sep;4(3):34. doi: 10.3978/j.issn.2304-3865.2015.09.01. Review.

32.

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ.

J Natl Compr Canc Netw. 2015 Sep;13(9):1061-4.

33.

Mechanisms of aromatase inhibitor resistance.

Ma CX, Reinert T, Chmielewska I, Ellis MJ.

Nat Rev Cancer. 2015 May;15(5):261-75. doi: 10.1038/nrc3920. Review.

PMID:
25907219
34.

Cognitive impairment after chemotherapy related to atypical network architecture for executive control.

Piccirillo JF, Hardin FM, Nicklaus J, Kallogjeri D, Wilson M, Ma CX, Coalson RS, Shimony J, Schlaggar BL.

Oncology. 2015;88(6):360-8. doi: 10.1159/000370117. Epub 2015 Feb 7.

35.

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE.

J Clin Oncol. 2015 Jan 20;33(3):265-71. doi: 10.1200/JCO.2014.57.6926. Epub 2014 Dec 15.

36.

US breast cancer mortality trends in young women according to race.

Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ.

Cancer. 2015 May 1;121(9):1469-76. doi: 10.1002/cncr.29178. Epub 2014 Dec 5.

37.

Body mass index, diabetes, and triple-negative breast cancer prognosis.

Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX.

Breast Cancer Res Treat. 2014 Jul;146(1):189-97. doi: 10.1007/s10549-014-3002-y. Epub 2014 May 29.

PMID:
24869799
38.

The Cancer Genome Atlas: clinical applications for breast cancer.

Ma CX, Ellis MJ.

Oncology (Williston Park). 2013 Dec;27(12):1263-9, 1274-9. Review.

39.

Incorporating genomics into breast cancer clinical trials and care.

Tabchy A, Ma CX, Bose R, Ellis MJ.

Clin Cancer Res. 2013 Dec 1;19(23):6371-9. doi: 10.1158/1078-0432.CCR-13-0837. Review.

40.

Targeted therapy for breast cancer.

Mohamed A, Krajewski K, Cakar B, Ma CX.

Am J Pathol. 2013 Oct;183(4):1096-1112. doi: 10.1016/j.ajpath.2013.07.005. Epub 2013 Aug 27. Review.

41.

Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.

Ademuyiwa FO, Ellis MJ, Ma CX.

J Oncol. 2013;2013:219869. doi: 10.1155/2013/219869. Epub 2013 Aug 1.

42.

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX.

Mol Cancer Ther. 2013 Aug;12(8):1665-75. doi: 10.1158/1535-7163.MCT-13-0159. Epub 2013 May 20.

43.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF.

Breast Cancer Res Treat. 2013 May;139(1):145-53. doi: 10.1007/s10549-013-2528-8. Epub 2013 Apr 19.

45.

Racial differences in outcomes of triple-negative breast cancer.

Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX.

Breast Cancer Res Treat. 2013 Feb;138(1):281-9. doi: 10.1007/s10549-012-2397-6. Epub 2013 Feb 12.

46.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM.

Breast Cancer Res Treat. 2013 Jan;137(2):483-92. doi: 10.1007/s10549-012-2378-9. Epub 2012 Dec 15.

47.

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ.

Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7.

48.

The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.

Nagaraj G, Ellis MJ, Ma CX.

Oncology (Williston Park). 2012 Aug;26(8):696-7, 700. No abstract available.

49.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

50.

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H.

J Clin Invest. 2012 Apr;122(4):1541-52. doi: 10.1172/JCI58765. Epub 2012 Mar 26. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.

Supplemental Content

Loading ...
Support Center